Funding for this research was provided by:
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016359)
Received: 7 March 2022
Revised: 3 May 2022
Accepted: 4 May 2022
First Online: 20 May 2022
: DLR has served as an advisor for AstraZeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Regeneron, Roche, Sanofi, Ventana, and Ultivue. Amgen, Cepheid, Konica Minolta, NavigateBP, NextCure, and Lilly have funded research in his lab. JK and KB are employees of Invicro, a division of Konica/Minolta. DCL and SH are employees of Protypia, Inc. Regan Fulton is the majority owner of Array Science, LLC and serves as a consultant to Leica Biosystems, Personalis, Inc., and Konica/Minolta (Invicro). All other authors declare no conflict of interest.
: All tissue samples were collected with the approval from the Yale Human Investigation Committee protocol #9505008219. Written informed consent, or waiver of consent, was obtained from all patients with the approval of the Yale Human Investigation Committee.